Biodesix, Inc. announced the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+ device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient's upper arm. Blood-based Nodify Lung testing, comprised of the Nodify CDT and Nodify XL2 tests, addresses a significant unmet need by assessing the risk of cancer in patients with lung nodules.

Biodesix offers a range of venous blood draw services, including an extensive network of mobile phlebotomists and independent laboratories. Capillary blood draws using the Tasso+ device enable blood specimen collection for healthcare providers who do not have convenient access to phlebotomy services or a licensed phlebotomist on staff in the clinic or office. The Tasso+ device was validated by Biodesix to be administered in minutes by any healthcare provider at the time of lung nodule evaluation, creating efficiencies in the Nodify Lung workflow.

Biodesix received approval from the New York State Clinical Laboratory Evaluation Program (NYS-CLEP) to use the Tasso+ device as a specimen collection method in support of Nodify Lung testing after entering into a supply agreement with Tasso, Inc. The device is now available for clinical use to collect specimens for Nodify Lung testing. Tasso+ is a trademark of Tasso, Inc.